Back Back
ProCE Banner Activity

CME

Critical Conversations in Melanoma: Expert Perspectives on Immunotherapy in Resectable and Unresectable Disease

Video

Watch this on-demand webcast from a June 2023 symposium featuring Allison Betof Warner, MD, PhD; Evan J. Lipson, MD; and Michael Postow, MD, on integrating the latest clinical guidance and expert recommendations for immunotherapy (collectively PD-1–, CTLA-4–, and LAG-3–directed immunotherapy) and targeted therapies (BRAF/MEK inhibitors) in early-stage and advanced-stage melanoma.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: June 21, 2023

Expiration: June 20, 2024

No longer available for credit.
Begin Activity

Share

Faculty

Allison Betof Warner

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Evan J. Lipson

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Michael Postow

Michael Postow, MD

Chief, Melanoma Service
Associate Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This program is intended for oncologists and other multidisciplinary care team members involved in the care of patients with melanoma.

Program Learning Goal

This program aims to improve learners’ knowledge, confidence, and competence in integrating the latest clinical guidance and expert recommendations for immunotherapy (collectively PD-1–, CTLA-4–, and LAG-3–directed immunotherapy) and targeted therapies (BRAF/MEK inhibitors) in early-stage and advanced-stage melanoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Consider evidence-based research findings and guideline recommendations for the use of immunotherapy (PD-1–, CTLA-4–, and LAG-3–directed immunotherapy) along with targeted therapies in melanoma, including adjuvant therapy, neoadjuvant therapy, or combined immunotherapy and targeted therapy for unresectable, metastatic disease

  • Devise treatment plans that incorporate immunotherapy for appropriate patients with resectable and unresectable melanoma, including those with BRAF-mutant or BRAF wild-type disease

  • Manage immune-related adverse events related to the use of immunotherapy in patients with melanoma across the spectrum of disease

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Allison Betof Warner, MD, PhD: consultant/advisor/speaker: Bristol-Myers Squibb, Immatics, Instil Bio, Iovance, Lyell Immunopharma, Novartis, Pfizer; researcher: Iovance.

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Evan Lipson, MD: consultant/advisor/speaker: Bristol-Myers Squibb, CareDx, Eisai, Genentech, Immunocore, InstillBio; researcher: Bristol-Myers Squibb, Merck, Sanofi/Regeneron.

Michael Postow, MD

Chief, Melanoma Service
Associate Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Michael Postow, MD: consultant/advisor/speaker: Bristol-Myers Squibb, Chugai, Eisai, Merck, Nektar, Novartis, Pfizer, Replimune; researcher: Bristol-Myers Squibb, Infinity, Merck, Novartis, RGenix.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 21, 2023, through June 20, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.